|  | No. | (%) |
---|---|---|---|
Region1 | NW Europe (UK, Austria, Belgium, Switzerland) | 1589 | (52%) |
 | Scandinavia (Norway, Sweden) | 501 | (17%) |
 | Australasia | 179 | (6%) |
 | Southern Europe (Italy, Portugal) | 408 | (13%) |
 | Eastern Europe (Poland) | 347 | (11%) |
 | Americas (Canada, Mexico) | 11 | (0%) |
Sex | Female | 1570 | (52%) |
 | Male | 1465 | (48%) |
Age | < = 70 years | 697 | (23%) |
 | > 70 years | 2338 | (77%) |
Age (more detail) | 18-50 | 127 | (4%) |
 | 51-60 | 203 | (7%) |
 | 61-70 | 367 | (12%) |
 | 71-80 | 721 | (24%) |
 | 81-90 | 1407 | (46%) |
 | over 90 | 210 | (7%) |
NIHSS2 | 0 to 5 | 612 | (20%) |
 | 6 to 10 | 852 | (28%) |
 | 11 to 15 | 601 | (20%) |
 | 16 to 20 | 542 | (18%) |
 | 21 to 35 | 428 | (14%) |
Stroke syndrome | Other | 2703 | (89%) |
 | Lacunar | 332 | (11%) |
Delay in randomisation | 0-3 hours | 849 | (28%) |
 | > 3 hours | 2186 | (72%) |
Delay (more detail) | 0-3 hours | 849 | (28%) |
 | 3-4.5 hours | 1178 | (39%) |
 | 4.5-6 hours | 1007 | (33%) |
 | > 6 hours3 | 1 | (0%) |
Antiplatelet agents < = 48 hours before randomisation | Yes | 1565 | (52%) |
 | No | 1470 | (48%) |